Filtered By:
Specialty: Cardiology
Condition: Heart Valve Disease

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 185 results found since Jan 2013.

Performing optimal transcatheter aortic valve implantation: The need for tailored use of transcatheter valves.
CONCLUSION: The choice of balloon-expandable or self-expanding transcatheter heart valve tailored to the patient's clinical and anatomical characteristics allows for maximal use of the transfemoral approach, and is associated with low 30-day rates of major complications and mortality. PMID: 31474571 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - August 28, 2019 Category: Cardiology Authors: Fischer Q, Urena M, Bouleti C, Abtan J, Brochet E, Carrasco JL, Iung B, Vahanian A, Himbert D Tags: Arch Cardiovasc Dis Source Type: research

Predictors of adverse outcomes after transcatheter mitral valve replacement.
Authors: Overtchouk P, Piazza N, Granada JF, Modine T Abstract Introduction: Transcatheter mitral valve replacement (TMVR) is still a recent technology with numerous unknowns but also great promises. The risk of complications reported in observational studies have limited its adoption by interventional cardiology and surgical communities. Areas covered: Some of the major setbacks of TMVR are complications related to the devices and those related to the pathway. Device-related complications include left ventricle outflow tract (LVOT) obstruction, transcatheter heart valve (THV) dislocation or embolization, thrombosi...
Source: Expert Review of Cardiovascular Therapy - August 15, 2019 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Incidence and outcome of peri-procedural transcatheter heart valve embolization and migration: the TRAVEL registry (TranscatheteR HeArt Valve EmboLization and Migration)
ConclusionTranscatheter valve embolization and migration occurred in approximately 1% and was associated with increased morbidity and mortality.
Source: European Heart Journal - June 23, 2019 Category: Cardiology Source Type: research

Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis
Conclusion  Compared with SAVR, TAVI is associated with reduction in all-cause mortality and stroke up to 2  years irrespective of baseline surgical risk and type of THV system.
Source: European Heart Journal - April 23, 2019 Category: Cardiology Source Type: research

Current status and future perspective of structural heart disease intervention.
Abstract Valvular heart diseases are one of the most frequent causes for heart failure. Degenerative diseases of the aortic and mitral valve as well as a dysfunctional tricuspid valve disease result in a worse clinical outcome if severe. Minimal-invasive, surgical and/or catheter-based structural heart disease (SHD) interventions have recently seen a dramatic increase. Transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (AS) is a disruptive technology, and next generation devices and careful patient selection will minimize limitations of TAVI such as paravalvular leak, conductance disturbance...
Source: Journal of Cardiology - April 3, 2019 Category: Cardiology Authors: Tabata N, Sinning JM, Kaikita K, Tsujita K, Nickenig G, Werner N Tags: J Cardiol Source Type: research

Prognostic significance of preoperative ECG Strain after Transcatheter Aortic Valve Replacement for severe Aortic Stenosis
ConclusionPreoperative ECG Strain was associated with higher risk of ME onset after TAVR for severe AS.
Source: Archives of Cardiovascular Diseases Supplements - March 22, 2019 Category: Cardiology Source Type: research

Non-vitamin K antagonist oral anticoagulants (NOACs) in the treatment of coronary and peripheral atherosclerosis. Expert Consensus.
Abstract Oral anticoagulants (OAC) are widely used for prevention of systemic thromboembolism, including the reduction of the risk of stroke in patients with atrial fibrillation (AF) and prosthetic heart valves. There is also an increasing population of patients who require not only OACs, but also double antiplatelet therapy (DAPT). A typical example is a patient with AF and stable coronary artery disease or acute coronary syndrome (ACS), treated by percutaneous coronary intervention (PCI). In recent years, with the introduction of NOACs, triple or dual therapy has become safer. Regardless of these indications for...
Source: Polish Heart Journal - February 25, 2019 Category: Cardiology Authors: Witkowski A, Barylski M, Filipiak KJ, Gierlotka M, Legutko J, Lesiak M, Stępińska J, Wojakowski W Tags: Kardiol Pol Source Type: research

Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
ConclusionsMorbidly obese AF patients treated with rivaroxaban had comparable risk of ischemic stroke/systemic embolism and major bleeding as those treated with warfarin, but lower healthcare resource utilization and costs.
Source: American Heart Journal - February 21, 2019 Category: Cardiology Source Type: research

Thromboembolic and bleeding risk stratification according to the EHRA valvular heart disease classification in patients with atrial fibrillation
ConclusionThis systematic analysis in real life conditions shows that distinguishing AF patients according to the new EHRA valve classification could be relevant for creating more homogenous groups of patients in terms of TE and bleeding risk. This clearer classification than the previous one should be useful as in clinical research for harmonization of studies, as well as in clinical practice for targeted choices of OAC therapy.
Source: Archives of Cardiovascular Diseases Supplements - December 25, 2018 Category: Cardiology Source Type: research

Treatment of Simultaneous Thromboembolism of the Right and Left Coronary Arteries with Thrombus Aspiration in a Patient with a Prosthetic Mitral Valve.
Authors: Sığırcı S, Keskin K, Sezai Yıldız S, Aksan G, Bambul Sığırcı B, Orta Kılıçkesmez K Abstract Prosthetic heart valve thrombosis is a rare, difficult-to-treat condition that increases morbidity and mortality by leading to systemic embolism. Clinically, it presents mainly in the form of stroke, though an embolism be observed in many systems. Acute coronary syndrome, which is rarely observed in patients with a prosthetic heart valve, mostly occurs as non-ST segment elevation myocardial infarction (MI). There is no specific recommendation for the treatment of this condition. Revascularization succes...
Source: Journal of Heart Valve Disease - December 19, 2018 Category: Cardiology Tags: J Heart Valve Dis Source Type: research

Early Hemodynamic Performance of the Crown PRT Aortic Prosthesis: A Prospective Study.
CONCLUSIONS: The Crown PRT is an effective bioprosthesis, with a low incidence of valve-related complications comparable to those of other current bioprostheses. The bioprosthesis demonstrated satisfactory results in terms of hemodynamics and freedom from reoperation. PMID: 30560604 [PubMed - in process]
Source: Journal of Heart Valve Disease - December 19, 2018 Category: Cardiology Tags: J Heart Valve Dis Source Type: research

Evolution of Veterans Affairs Transcatheter Aortic Valve Replacement Program: The First 100 Patients.
CONCLUSIONS: Successful outcomes were demonstrated for a VA TAVR program that compared favorably with benchmarks established by the National Transcatheter Valve Therapies Registry. These results provide a necessary transparency of TAVR outcomes at a federal institution. PMID: 30560596 [PubMed - in process]
Source: Journal of Heart Valve Disease - December 19, 2018 Category: Cardiology Tags: J Heart Valve Dis Source Type: research

Transfemoral aortic valve implantation with new-generation devices: the repositionable Lotus vs. the balloon-expandable Edwards Sapien 3 valve
Background New-generation transcatheter heart valves have been developed to reduce complications of transcatheter aortic valve implantation (TAVI). With this study we sought to compare procedural and 30-day outcomes of the new-generation repositionable Boston Scientific Lotus (Lotus) and the balloon-expandable Edwards Sapien 3 (ES3) transcatheter heart valves. Methods A total of 315 patients with severe symptomatic aortic stenosis undergoing transfemoral TAVI with Lotus or ES3 included in two large Italian registries were considered for this analysis. After propensity matching, 93 matched pairs of patients were includ...
Source: Journal of Cardiovascular Medicine - October 9, 2018 Category: Cardiology Tags: Research articles: Interventional cardiology Source Type: research

Outcomes with a latest generation self-expandable, intra-annular, re-sheathable transcatheter heart valve system: analysis of patients with impaired left ventricular function and determinants for pacemaker implantation
ConclusionsThe Portico valve demonstrates a satisfying safety outcome, especially for patients with impaired LV function. Results of the CE-mark trial were confirmed, except for higher PPM rates. PPM rates are in accordance with other reports on this TAVI platform.
Source: Clinical Research in Cardiology - October 1, 2018 Category: Cardiology Source Type: research

MitraClip ® Implantation Under Cerebral Protection: A Case Report.
MitraClip® Implantation Under Cerebral Protection: A Case Report. J Heart Valve Dis. 2017 Nov;26(6):728-730 Authors: Pohl J, Luedike P, Alexander Jánosi R, Rassaf T Abstract MitraClip® implantation is commonly used in patients with severe mitral regurgitation (MR) and who are at high risk for surgical mitral valve repair. The occurrence of stroke or transient ischemic attack is a potential complication in patients undergoing MitraClip implantation, and incidences of up to 2.6% have been reported. Herein is reported the case of an 84-year-old woman with severe MR and a thin filamentous structure at t...
Source: Journal of Heart Valve Disease - September 13, 2018 Category: Cardiology Tags: J Heart Valve Dis Source Type: research